Evidence map›Paper›PMID 40399232›Full record

ReviewChembiochem : a European journal of chemical biology2025

Designing the Proteome with Chemical Tools: Degrons and Beyond.

Laurence J Seabrook, Catherine R Livelo, Lauren V Albrecht

Abstract readReview
In one paragraph

Review in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laurence J SeabrookDepartment of Developmental and Cell Biology, University of California, Irvine, Irvine, CA, 92697, USA.ORCID https://orcid.org/0000-0002-9337-9712
Catherine R LiveloDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, 92697, USA.ORCID https://orcid.org/0009-0007-0298-4698
Lauren V AlbrechtDepartment of Developmental and Cell Biology, University of California, Irvine, Irvine, CA, 92697, USA.ORCID https://orcid.org/0000-0002-3147-8010

Funding

Deciphering Novel Principles of Rapid Proteostatic Control and Innovating Spatiotemporal Lysosomal ToolsR35GM157370 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lauren Veronica Albrecht · 2024 to 2026
$1.1M
Alfred P. Sloan FoundationNIGMS NIH HHS R35 GM157370NIGMS NIH HHS R35GM157370
6 · The paper itself

Abstract

Cell biology relies on precise changes in protein stability, which can be chemically harnessed to transform cell fate. Decades of research have revealed the many intricate systems underlying cellular proteostasis, which can be hijacked by proximity-based degrader compounds. The archetypal degrader, proteolysis targeting chimera, recruits E3 ligases to protein targets to facilitate their ubiquitination and degradation in the proteasome. Being able to customize the human proteome with chemical tools has great value for fundamental research and for clinical progress through the controlled elimination of disease-causing proteins. Success within the degrader field has reinvigorated interest in mapping the mechanisms underlying native protein degradation, which has platformed new degrader classes capable of advancing the field toward the goal of degrading the entire human proteome. This review discusses ongoing strategies to identify degrons regulating native protein turnover, advances in chemical tools to activate these degrons, and new attempts to streamline degron pathways for simplified targeted protein degradation. The continued discovery and application of degrons has the power to transform human biology and combat disease.

Indexed as

ProteomeDegronsHumansProteasome Endopeptidase ComplexProteolysisUbiquitinationUbiquitin-Protein LigasesProteasome Endopeptidase ComplexProteomeUbiquitin-Protein Ligasesdegronslysosomesproteasomesproteolysis targeting chimerastargeted protein degradation

Identifiers

PMID40399232
PMCPMC13526462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.